Revolution Medicines Inc Cash Flow Conversion Efficiency
Revolution Medicines Inc cash flow conversion efficiency. Based on the latest financial reports, Revolution Medicines Inc (RVMD) has a cash flow conversion efficiency ratio of -0.149x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-387.32 Million) by net assets ($2.61 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Revolution Medicines Inc (2017–2025)
Cash flow conversion efficiency of Revolution Medicines Inc from 2017 to 2025. This chart illustrates how Revolution Medicines Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of Revolution Medicines Inc for real-time trading data and today's change.
Revolution Medicines Inc Cash Flow Conversion Ratio Explained
Revolution Medicines Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Revolution Medicines Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Revolution Medicines Inc ranked by their cash flow conversion efficiency. Also see RVMD stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ameriprise Financial Inc
NYSE:AMP
|
0.074x |
|
WEG S.A.
SA:WEGE3
|
0.059x |
|
Astera Labs, Inc.
NASDAQ:ALAB
|
0.051x |
|
ASM INTL N.V. NY/1 EO-04
F:AVSN
|
0.010x |
|
LEGRAND UNSP.ARD 1/5 EO 4
F:LRC0
|
0.033x |
|
Nanya Technology Corp
TW:2408
|
-0.006x |
|
Itaú Unibanco Holding S.A
F:BVXB
|
-0.202x |
|
CSL LTD SPON.ADR 2
F:CSJA
|
N/A |
Annual Cash Flow Conversion Efficiency for Revolution Medicines Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Revolution Medicines Inc from 2017 to 2025. Review Revolution Medicines Inc free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $1.63 Billion | $-897.74 Million | -0.550x | -123.63% |
| 2024-12-31 | $2.27 Billion | $-557.44 Million | -0.246x | -28.19% |
| 2023-12-31 | $1.83 Billion | $-350.57 Million | -0.192x | +41.38% |
| 2022-12-31 | $685.19 Million | $-224.40 Million | -0.328x | -34.08% |
| 2021-12-31 | $602.57 Million | $-147.18 Million | -0.244x | -15.87% |
| 2020-12-31 | $474.68 Million | $-100.06 Million | -0.211x | +35.19% |
| 2019-12-31 | $152.53 Million | $-49.62 Million | -0.325x | -2691.99% |
| 2018-12-31 | $96.66 Million | $1.21 Million | 0.013x | +100.23% |
| 2017-12-31 | $4.53 Million | $-25.15 Million | -5.550x | -- |
About Revolution Medicines Inc
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS comp… Read more